Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed  

作　　者：Ken Sato 

机构地区：[1]Department of Healthcare Informatics,Takasaki University of Health and Welfare,Takasaki 370-0033,Japan [2]Department of Gastroenterology and Hepatology,Gunma University Graduate School of Medicine,Maebashi 371-8511,Japan

出　　处：《World Journal of Gastroenterology》2025年第10期151-158,共8页世界胃肠病学杂志(英文)

摘　　要：In the recent issue of the World Journal of Gastroenterology,Han et al compared the efficacy of and adverse reactions to bevacizumab versus lenvatinib as molecularly targeted agents in combination with interventional therapy and immunotherapy(IMT)to treat intermediate-to-advanced unresectable hepatocellular carcinoma.No significant differences in efficacy or adverse reactions were observed between bevacizumab and lenvatinib.This study is highly promising because in some regions,e.g.,Japan,the combination of molecularly targeted therapy with IMT is fixed because of insurance restrictions,and some molecularly targeted agents cannot be combined with IMT.Further studies using these three modalities are expected to be conducted in the future.Additionally,because advanced radiotherapy modalities have recently been established,the number of combinations continues to increase,and further evidence regarding combination therapy,which is the cornerstone of personalized medicine,needs to be accumulated.

关 键 词：Hepatocellular carcinoma Molecularly targeted therapy IMMUNOTHERAPY Interventional therapy Radiation therapy 

分 类 号：R563.1[医药卫生—呼吸系统] R575[医药卫生—内科学]